PLZ4-coated paclitaxel micelles advance to Phase I trial for refractory non-muscle-invasive bladder cancer
Background
Bladder cancer, particularly non-muscle-invasive bladder cancer (NMIBC), is characterized by high recurrence rates despite current intravesical therapies. Standard treatments often provide limited long-term benefit, necessitating novel localized strategies. This trial investigates PLZ4-coated paclitaxel-loaded micelles, a targeted drug delivery system, to improve therapeutic efficacy and reduce systemic toxicity for patients with refractory NMIBC. The approach aims to overcome limitations of traditional chemotherapy by enhancing drug accumulation at the tumor site.
Study Design
This Phase I, open-label, dose-escalation trial (NCT06173349) is recruiting patients with refractory non-muscle-invasive bladder cancer (NMIBC). Participants will receive intravesical instillations of PLZ4-coated paclitaxel-loaded micelles. The study's primary objective is to assess the safety and tolerability of the micelles, determining the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs). Secondary endpoints include preliminary efficacy, pharmacokinetics, and pharmacodynamics.
Why It Matters
This trial represents a crucial step towards a novel localized treatment for refractory NMIBC, a condition with significant unmet needs. If successful, PLZ4-coated paclitaxel-loaded micelles could offer a more effective intravesical therapy, potentially reducing recurrence rates and improving patient outcomes compared to current options. The targeted delivery system aims to minimize systemic side effects, enhancing the safety profile of paclitaxel. Future studies will need to confirm efficacy in larger cohorts and establish optimal dosing protocols.
bladder cancer
nmibc
paclitaxel
micelles
drug delivery
phase 1 trial